Bladder Cancer Weekly

May 25, 2026

Videos

Peer-to-Peer Clinical Conversations

Moving Beyond Repeat TURBT in Recurrent NMIBC - John Sfakianos

John Sfakianos

John Sfakianos discusses non-surgical management of bladder cancer, focusing on chemoablation and bladder preservation.

OPTIMA II Five-Year Data: Mitomycin Chemoablation Provides Durable Response in LG-IR-NMIBC - Neal Shore

Neal Shore

Neal Shore to discusses chemoablation with mitomycin (ZUSDURI™) for low-grade intermediate-risk non-muscle invasive bladder cancer.

Beyond the Abstracts

Real-World Treatment Sequences and Overall Survival in Metastatic Bladder Cancer: The STATES-Bladder Study - Beyond the Abstract

Contemporary Practice Patterns in Female Radical Cystectomy: Results of a UK and Ireland Survey - Beyond the Abstract

Conference Coverage

AUA 2026: An Indirect Treatment Comparison (ITC) of Nogapendekin Alfa Inbakicept-pmln plus Bacillus Calmette–Guérin (NAI+BCG) and TAR-200 in patients with BCG-unresponsive, Non-Muscle Invasive Bladder Cancer CIS ± Papillary (NMIBC)

AUA 2026: Disitamab Vedotin plus BCG Intravesical Instillation in Patients with HER2 High Expression High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC): Efficacy and Safety Results from the Phase II Formula-01 Trial

AUA 2026: SUO-CTC: Bladder Trials Update

AUA 2026: Perioperative and Oncologic Outcomes of Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and Pembrolizumab: A Multicenter Experience

AUA 2026: Differences in Patient-Reported and Objective Functional Recovery Trajectories Following Radical Cystectomy: Findings from the UW Prospective Bounceback Cohort Study

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.

Development and validation of a machine learning model for predicting 30-day major morbidity and mortality following radical cystectomy: An American College of Surgeons National Surgical Quality Improvement Program study.

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin.

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

Role of Bladder EpiCheck® in Bladder cancer: from primary diagnosis to surveillance.

Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a Diverse, Urban Population.

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Survivor-identified barriers and facilitators to acute phase recovery following radical cystectomy.

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study.

Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder Cancer.

Non-muscle-invasive urothelial carcinoma of the bladder: time for a de-escalation of treatment and aftercare.

Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.

Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.

Impact of Pelvic Lymph Node Dissection on Oncological Outcomes in Patients with Clinically Staged Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Systematic Review - Beyond the Abstract

Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design - Beyond the Abstract

Population-Based Outcomes of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer in Older Adults - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC